Since no eligible APM options for urology currently exist, the Centers for Medicare and Medicaid Services (CMS) recognized the need for specialty-specific APMs and created a process by which stakeholders, like LUGPA, can develop and submit specific APM models for CMS review and approval. For an independent urology practice to benefit from an APM, providers need integrated clinical and financial systems that can monitor not only treatment pathway adherence and quality metrics, but also patient outcomes and practice costs.
After an extensive search, LUGPA selected Integra Connect as its partner to develop urology-specific APMs, based on Integra Connect's deep experience with population health management and payer initiatives which will assist LUGPA with the MACRA transition to value-based care.
Initially, LUGPA will develop two APM projects with LUGPA practice involvement:
- Prostate Cancer Biopsy Taking Risk on Sepsis; and
- Positive Biopsy/Localized Prostate Cancer.